Clinical trials: Oligometastases, open to volunteers
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Lung Cancer (NSCLC)
Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study
The goal of this observational study is to evaluate the performances of a percutaneous Pulsed Electrical Field (PEF) ablation to treat patients with primary early-stage lung cancer (NSCLC) or lung oligometastatic Tumors who are…
- Trial name
- NCT07799194
- Testing
- Pulsed Electric Field Ablation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Energenx Medical LTD.
Lung Cancer
Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging
This trial will investigate the feasibility of the Markerless Tumour Tracking technology.
- Trial name
- MAGIK (NCT04086082)
- Testing
- Markerless Image Guidance
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- University of Sydney
Melanoma Metastatic
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body.
- Trial name
- AXIOM (NCT06767306)
- Testing
- Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone
- Where
- 5 sites in Australia, Canada
- Volunteers
- 129 people
- Sponsor
- Melanoma Institute Australia
Spinal Metastases, Spinal Tumor
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the…
- Conditions
- Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
- Trial name
- NCT06120426
- Testing
- total en bloc spondylectomy
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Metastatic Tumor
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs.
- Trial name
- SABR-SYNC (NCT05717166)
- Testing
- Palliative Radiotherapy, Chemotherapy, Hormone therapy
- Where
- 5 sites in Canada, Switzerland
- Volunteers
- 180 people
- Sponsor
- David Palma
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
Ovarian Cancer Recurrent
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and…
- Trial name
- SOPRANO (NCT05990192)
- Testing
- Niraparib oral capsule, SBRT
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
Non Small Cell Lung Cancer NSCLC
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses…
- Trial name
- AUSTRAL (NCT06680050)
- Testing
- Durvalumab (MEDI4736), Ceralasertib, radiotherapy
- Where
- 9 sites in Italy, Switzerland
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Oligo-metastatic Cancer
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
The combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease.
- Trial name
- NCT07481799
- Testing
- Becotatug Vedotin, SBRT, Systemic Therapy/Standard of Care
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Ming-Yuan Chen
Oligometastatic Disease, Non-small Cell Lung Cancer
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
- Conditions
- Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
- Trial name
- TARGET-01 (NCT05277844)
- Testing
- Local Consolidative Radiation Therapy, TKI
- Where
- India
- Volunteers
- 106 people
- Sponsor
- Tata Memorial Hospital
Adaptive Radiotherapy, Stereotactic Body Radiotherapy
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or…
- Conditions
- Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
- Trial name
- NCT06542159
- Testing
- Online adaptive SBRT, Conventional SBRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Lymph Node Oligometastases
Adaptive Fractionation in Online Adaptive Stereotactic Radiotherapy for Abdominopelvic Lymph Node Oligometastases
Oligometastases, a state of cancer with up to five metastases, was traditionally treated with systemic treatments like chemotherapy.
- Trial name
- STEAL-3 (NCT07415356)
- Testing
- Online-Adaptive SBRT
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Joost J. M. E. Nuyttens
Oncology, Breast Cancer
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further…
- Conditions
- Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
- Trial name
- MOMENTUM (NCT04075305)
- Testing
- Radiation therapy
- Where
- 18 sites in United States, Australia and 7 more
- Volunteers
- 8,000 people
- Sponsor
- UMC Utrecht
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University
Advanced Esophageal Squamous Carcinoma With Oligometastases
Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.
A randomized, prospective phase II trial was conducted to explore the timing of radiotherapy intervention in combination with chemotherapy and immunotherap in order to provide an effective treatment for patients with advanced…
- Trial name
- NCT06143722
- Testing
- simultaneous with radiotherapy, synchronous with radiotherapy
- Volunteers
- 63 people
- Sponsor
- West China Hospital